Lookup NU author(s): Professor Farhad Kamali,
Professor Ann Daly
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
There have recently been significant advances in the field of oral anticoagulation, but these have also led to many controversies. Warfarin is still the commonest drug used for clotting disorders but its use is complicated owing to wide inter-individual variability in dose requirement and its narrow therapeutic index. Warfarin dose requirement can be influenced by both genetic and environmental factors. Two recent randomized controlled trials (RCTs) came to different conclusion regarding the utility of genotype-guided dosing; we critically explore the reasons for the differences. The new generation of oral anticoagulants have been demonstrated to be as efficacious as warfarin, but further work is needed to evaluate their safety in real clinical settings.
Author(s): Pirmohamed M, Kamali F, Daly AK, Wadelius M
Publication type: Review
Publication status: Published
Journal: Trends in Pharmacological Sciences
Print publication date: 01/03/2015
Online publication date: 17/02/2015
ISSN (print): 0165-6147
ISSN (electronic): 1873-3735
Publisher: ELSEVIER SCIENCE LONDON